G. Ossenkoppele

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

L. Bullinger, J. Hernández-Rivas, P. Williamson, 2019, Trials.

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

E. Vellenga, M. Jongen‐Lavrencic, M. Vekemans, 2021, Cancers.

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

S. Iacobelli, D. Hasenclever, M. Mohty, 2022, Blood.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

E. Vellenga, J. Passweg, T. Pabst, 2015, The Lancet. Haematology.

ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies (ESMO-MCBS:H) Version 1.0.

M. Piccart, B. Gyawali, U. Dafni, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

J. E. Butler, L. Bullinger, K. Döhner, 2022, Blood.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

E. Vellenga, F. Baron, G. Meloni, 2016, Leukemia.

Acute Myeloid Leukemia

M. Millenson, F. Appelbaum, M. Tallman, 2019, The New England journal of medicine.

Acute myeloid leukemia

G. Ossenkoppele, 2018, Methods in Molecular Biology.